Anc80 encoding sphingolipid-metabolizing proteins
AssigneeIcahn School of Medicine at Mount Sinai
InventorsEfrat ELIYAHU, Adam VINCEK, Michael KATZ
Life of this patent
Estimating the term…
Abstract
The present disclosure pertains to the use of an Anc80 viral vector that encodes a sphingolipid-metabolizing protein such as acid ceramidase to achieve expression of the sphingolipid-metabolizing protein in a mammalian cell or group of cells. Expression of the protein from the Anc80 vector reduces high levels of ceramide in the cell that lead to cell death or senescence.
Claims20
A method to inhibit cell death and/or cell senescence and promote survival of a mammalian cell or group of cells comprising contacting said cell or cells with an Anc80 viral vector encoding a sphingolipid-metabolizing protein.
A method to inhibit cell death and/or cell senescence and promote survival of a mammalian cell or group of cells in vivo comprising contacting said cell or cells with an a sphingolipid-metabolizing protein or an Anc80 viral vector encoding a sphingolipid-metabolizing protein.
A method for preserving and/or restoring heart function in a subject following ischemia, reperfusion injury or myocardial infarction (MI), the method comprising administering to the subject a therapeutically effective amount of an Anc80 viral vector encoding a sphingolipid-metabolizing protein.
The method of claim 12, wherein Anc80 has the nucleotide sequence of SEQ ID NO:
- 20.
A pharmaceutical composition comprising an Anc80 viral vector encoding a sphingolipid-metabolizing protein and a pharmaceutically acceptable carrier.
An Anc80 viral vector encoding a sphingolipid-metabolizing protein for use in the treatment of MI, ischemia or reperfusion injury.
An Anc80 viral vector encoding a sphingolipid-metabolizing protein for use in preserving and/or restoring function in cardiac cells following ischemia, reperfusion injury or myocardial infarction (MI).
Dependencies are inferred from the claim text.